YOLFTbeta
Invion Ltd

Invion Ltd

IVX · AU · Healthcare / Drug Manufacturers - Specialty & Generic

0.033AUD-0.00 (-10.81%)

Price History

Full chart

Market Stats

Previous Close0.037
Open0.034
Day Range0.033 – 0.034
52-Week Range0.032 – 0.11
Volume183.50K
Market Cap4.15M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.06
Dividend Yield0.00%
Beta0.42
50-Day Avg0.0396
200-Day Avg0.0592

About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Thian Chew
  • Employees0
  • Headquarters385 Bourke Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.inviongroup.com

Leadership

  • Mr. Thian ChewExecutive Chairman & CEO
  • Ms. Melanie Jaye Leydin B.Bus, C.A.CFO, Company Secretary & Non-Executive Director · b. 1973
  • Dr. Dean NaylorHead of Intellectual Property Development

Financials

Income Statement

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue3.00K40.00K22.00K24.00K1.46M4.59M---140.00K143.00K93.00K-207.34K185.35K139.10K0737.71K3.88M3.48M2.33M3.29M4.10M3.69M0385.32K
Growth (%)-+1233.33%-45.00%+9.09%+5966.67%+215.18%----+2.14%-34.97%---10.60%-24.95%-100.00%-+426.23%-10.44%-32.98%+41.28%+24.70%-10.00%-100.00%-
Cost of Revenue5.00K107.00K810.00K1.32M459.00K2.30M530.00K745.00K702.00K294.00K544.00K1.72M1.86M2.29M9.02M1.32M1.24M370.89K2.26M1.56M1.52M2.32M2.90M2.69M1.29M-
Gross Profit-------------1.86M-2.08M-8.84M-1.18M-1.24M366.83K1.63M1.92M810.50K969.12K1.21M1.00M-1.29M385.32K
Gross Margin--------------1004.01%-4767.50%-849.27%-49.72%41.86%55.12%34.79%29.44%29.39%27.16%-100.00%
Operating Expense------------3.84M6.20M6.00M5.02M840.42K1.33M4.14M2.94M2.38M3.29M2.85M6.68M4.00M4.33M
Operating Income------13.96M-17.85M-21.56M--13.61M-12.01M-4.62M-5.70M-8.28M-14.84M-6.20M-2.09M-960.47K-2.52M-1.03M-1.57M-2.32M-1.65M-5.68M-5.29M-3.94M
Operating Margin------304.31%----9724.32%-8401.65%-4969.13%--3994.55%-8004.76%-4456.92%--130.20%-64.85%-29.52%-67.48%-70.52%-40.16%-153.68%--1022.75%
EBITDA------10.91M-15.71M-20.59M--13.38M-11.87M-7.23M-5.68M-6.32M-13.49M-4.61M-840.42K-2.93M-2.21M-748.56K-1.29M-1.82M-965.37K-4.57M-4.00M-3.94M
EBITDA Margin------237.75%----9558.11%-8300.65%-7770.63%--3048.21%-7280.09%-3312.25%--397.15%-56.87%-21.53%-55.56%-55.26%-23.52%-123.75%--1022.75%
Net Income------11.95M-16.12M-21.02M--16.79M-13.68M-5.54M-5.17M-6.88M-13.04M-4.45M-2.20M-926.51K-2.55M-953.89K-1.48M-2.24M-1.61M-5.63M-8.81M-5.63M
Net Income Margin------260.35%----11990.85%-9566.43%-5957.98%--3320.17%-7035.81%-3197.49%--125.59%-65.59%-27.44%-63.65%-68.09%-39.34%-152.34%--1461.90%
R&D336.00K273.00K1.21M2.62M2.47M8.97M10.71M9.57M7.35M5.43M5.14M1.18M1.53M1.85M8.69M1.30M30.89K363.66K2.23M1.55M1.52M2.32M2.90M2.69M1.29M1.48M
R&D as % of Total Revenue11200.00%682.50%5518.18%10908.33%169.44%195.52%---3877.94%3597.26%1271.42%-892.64%4687.92%936.01%-49.30%57.45%44.62%65.21%70.56%70.61%72.84%-384.83%
Interest Expense0000032.86K109135.71K03.17M1.67M886.19K80119.41K1.11M199.61K144.38K117.93K00053-240.00K694.77K-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.72%---2266.53%1164.78%952.89%-9.36%596.69%143.50%-15.99%0.00%0.00%0.00%0.00%-6.50%--

Balance Sheet

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.44M1.48M2.06M2.53M13.64M13.95M3.74M3.24M24.32M4.49M4.73M6.83M16.25M14.73M16.10M11.98M5.81M10.35M6.06M5.76M5.64M20.04M19.05M15.45M9.49M8.17M
Total Liabilities1.40M1.74M1.53M1.94M11.73M9.11M3.02M6.46M12.18M9.26M6.87M815.52K5.21M4.57M9.24M5.99M1.80M2.44M604.71K326.82K851.50K462.41K650.63K1.01M1.24M2.85M
Total Equity40.00K-529.00K591.00K739.00K2.51M715.28K-3.23M12.14M-4.78M-2.14M6.01M11.04M10.16M6.86M5.99M4.01M7.91M5.46M5.43M4.79M19.58M18.40M14.44M8.25M5.32M
Cash-249.00K137.00K1.20M1.82M420.00K156.00K36.00K23.65M3.43M3.91M4.19M3.05M3.95M2.28M437.40K917.49K2.89M771.31K618.84K1.04M8.47M4.08M783.53K850.37K592.31K
Total Debt-----7.08M200.00K272.89K1.54M3.62M2.33M-16.17K15.92K2.58M3.81M3.74M20.30K-------1.55M
Net Debt-----7.08M200.00K272.89K-22.11M183.47K-1.58M-4.19M-3.03M-3.94M294.23K3.37M2.83M-2.87M-771.31K-618.84K-1.04M-8.47M-4.08M-783.53K-850.37K955.25K

Cash Flow

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow------11.87M-12.26M-9.86M--15.20M-13.46M-10.62M-3.46M-4.35M-10.13M-3.83M-247.14K707.09K-2.11M-152.47K417.98K-1.11M-1.81M-2.40M-2.97M-2.37M
Investing Cash Flow----629.00K-1.09M7.09M1.46M--10.72K-44.12K-118.90K-443.21K-221.48K-245.83K25.07K53.87K-13.61K-13.61K-7.25M-7.25M-7.25M-2.58M-900.00K0-68.83K
Financing Cash Flow272.00K1.38M2.09M5.80M6.93M11.56M4.90M8.28M6.54M18.61M13.66M11.02M2.90M5.53M8.66M1.89M678.87K1.27M15.80M15.80M15.80M15.80M15.80M03.04M2.18M
Capital Expenditure8.00K59.00K127.00K154.00K364.00K1.16M302.71K25.19K60.00K10.72K44.12K169.44K5.49K20.87K8.32K1366.05K6.05K6.05K75.83K7.25M7.25M2.58M900.00K04.11K
Free Cash Flow------13.03M-12.56M-9.89M--15.21M-13.50M-10.79M-3.46M-4.37M-10.14M-3.83M-247.14K707.09K-2.11M-152.47K417.98K-8.36M-4.39M-3.30M-2.97M-2.38M
Dividends Paid---------8.17M3.08M433.23K115.32K-4.03M1.68M663.45K982.01K--------
FCF to OCF-----109.80%102.47%100.26%-100.07%100.33%101.60%100.16%100.48%100.08%100.00%100.00%100.00%100.29%100.00%100.00%753.80%242.10%137.48%100.00%100.17%
Dividend Paid to FCF----------53.69%-22.82%-4.02%-3.33%--39.79%-43.88%-268.45%138.88%--------

Earnings

Report DateFeb 26, 2016Aug 30, 2016Feb 27, 2017Aug 31, 2017Feb 27, 2018Aug 28, 2018Feb 26, 2019Aug 28, 2019Feb 24, 2020Aug 26, 2020Feb 25, 2021Aug 4, 2021Feb 22, 2022Aug 17, 2022Feb 23, 2023Feb 28, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-
EPS Actual0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.03-0.09
Surprise-----------------
Timing-------------After-hoursAfter-hours--

Key Statistics & Ratios

Market Cap4.15M
Enterprise Value5.10M
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.79
Price / Book0.78
EPS-0.06
Book Value0.049
Revenue (TTM)384.71K
Gross Profit (TTM)-1.10M
EBITDA-3.94M
Profit Margin0.00%
Operating Margin-567.07%
Return on Equity-83.02%
Return on Assets-40.10%
Shares Outstanding109.20M
Shares Float64.65M
Beta0.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 20, 20241:100
  • Feb 14, 2018875:691
  • Mar 24, 201581:73
  • Feb 28, 20141659:1655
  • Sep 7, 2011110:107
  • Sep 29, 2010204:199